2013 Fiscal Year Final Research Report
A new treatment for choroidal, retinal and corneal neovascularization with targeting to alfa-9 integrin ligand
| Project/Area Number |
22791680
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Ophthalmology
|
|---|
| Research Institution | Wakayama Medical University |
|---|
Principal Investigator |
FUJITA Norihito 和歌山県立医科大学, 医学部, 博士研究員 (10453177)
|
|---|
| Project Period (FY) |
2010-04-01 – 2014-03-31
|
| Keywords | α９インテグリン / 血管新生 / 脈絡膜 / 角膜 / 網膜 |
|---|
| Research Abstract |
This study provide evidence that endogenous alfa-9 integrin ligand including osteopontin or tenascin-C at physiological levels inhibits induced angiogenesis in laser-induced choroidal neovascularization (CNV) in vivo. Mechanism of action might include the effects of alfa-9 integrin ligand on vascular endothelial cells. Blocking alfa-9 integrin ligand activity might be a potential strategy for the prevention or treatment of CNV in an age-related macular degeneration (AMD) patient. A clinical trial by using antibody is to be set up for establishment of a new AMD treatment strategy.
|
